Retinal neovascularization is prevented by blockade of the renin-angiotensin system

被引:211
作者
Moravski, CJ
Kelly, DJ
Cooper, ME
Gilbert, RE
Bertram, JF
Shahinfar, S
Skinner, SL
Wilkinson-Berka, JL [1 ]
机构
[1] Univ Melbourne, Dept Physiol, Parkville, Vic 3010, Australia
[2] Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic 3065, Australia
[3] Univ Melbourne, Dept Med, Austin & Repatriat Med Ctr, Heidelberg West, Vic, Australia
[4] Monash Univ, Dept Anat, Clayton, Vic 3168, Australia
[5] Merck Res Labs, Blue Bell, PA USA
关键词
renin; growth substances; angiotensin; renin-angiotensin system;
D O I
10.1161/01.HYP.36.6.1099
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Both angiotensin II and vascular endothelial growth factor are angiogenic agents that have recently been implicated in the pathogenesis of proliferative diabetic retinopathy. In this study, retinal neovascularization was examined in a model of retinopathy of prematurity with the use of neonatal transgenic (mRen-2)27 rats, which overexpress renin in tissues, and Sprague-Dawley rats. Blockers of the renin-angiotensin system were administered during the neovascularization period, The ACE inhibitor lisinopril and the angiotensin type 1 receptor antagonist losartan both increased retinal renin levels and prevented inner retinal blood vessel growth. Quantitative in situ hybridization revealed that the expression of vascular endothelial growth factor and its type 2 receptor in the inner retina and proliferating blood vessels were increased in rats with retinopathy of prematurity, Lisinopril reduced both retinal vascular endothelial growth factor and its type 2 receptor mRNA in retinopathy of prematurity rats, whereas losartan had no effect, It is predicted that agents that interrupt the renin-angiotensin system may play an important role as retinoprotective agents in various forms of proliferative retinopathy.
引用
收藏
页码:1099 / 1104
页数:6
相关论文
共 28 条
[1]   SUPPRESSION OF RETINAL NEOVASCULARIZATION IN-VIVO BY INHIBITION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR (VEGF) USING SOLUBLE VEGF-RECEPTOR CHIMERIC PROTEINS [J].
AIELLO, LP ;
PIERCE, EA ;
FOLEY, ED ;
TAKAGI, H ;
CHEN, H ;
RIDDLE, L ;
FERRARA, N ;
KING, GL ;
SMITH, LEH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (23) :10457-10461
[2]   VASCULAR ENDOTHELIAL GROWTH-FACTOR IN OCULAR FLUID OF PATIENTS WITH DIABETIC-RETINOPATHY AND OTHER RETINAL DISORDERS [J].
AIELLO, LP ;
AVERY, RL ;
ARRIGG, PG ;
KEYT, BA ;
JAMPEL, HD ;
SHAH, ST ;
PASQUALE, LR ;
THIEME, H ;
IWAMOTO, MA ;
PARK, JE ;
NGUYEN, HV ;
AIELLO, LM ;
FERRARA, N ;
KING, GL .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (22) :1480-1487
[3]  
BATTEGAY EJ, 1995, J MOL MED, V73, P333
[4]  
BERKA JL, 1995, INVEST OPHTH VIS SCI, V36, P1450
[5]   RENIN PROCESSING STUDIED BY IMMUNOGOLD LOCALIZATION OF PRORENIN AND RENIN IN GRANULAR JUXTAGLOMERULAR CELLS IN MICE TREATED WITH ENALAPRIL [J].
BERKA, JLA ;
ALCORN, D ;
RYAN, GB ;
SKINNER, SL .
CELL AND TISSUE RESEARCH, 1992, 268 (01) :141-148
[6]   Vascular changes in retinas of spontaneously hypertensive rats demonstrated by corrosion casts [J].
Bhutto, IA ;
Amemiya, T .
OPHTHALMIC RESEARCH, 1997, 29 (01) :12-23
[7]   Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes [J].
Chaturvedi, N ;
Sjolie, AK ;
Stephenson, JM ;
Abrahamian, H ;
Keipes, M ;
Castellarin, A ;
Rogulja-Pepeonik, Z ;
Fuller, JH .
LANCET, 1998, 351 (9095) :28-31
[8]   RENIN, PRORENIN, AND IMMUNOREACTIVE RENIN IN VITREOUS FLUID FROM EYES WITH AND WITHOUT DIABETIC-RETINOPATHY [J].
DANSER, AHJ ;
VANDENDORPEL, MA ;
DEINUM, J ;
DERKX, FHM ;
FRANKEN, AAM ;
PEPERKAMP, E ;
DEJONG, PTVM ;
SCHALEKAMP, MADH .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1989, 68 (01) :160-167
[9]  
DANSER AHJ, 1994, INVEST OPHTH VIS SCI, V35, P1008
[10]   IDENTIFICATION AND QUANTIFICATION OF RENIN AND PRORENIN IN THE BOVINE EYE [J].
DEINUM, J ;
DERKX, FHM ;
DANSER, AHJ ;
SCHALEKAMP, MADH .
ENDOCRINOLOGY, 1990, 126 (03) :1673-1682